Patents by Inventor Philip Nadeau

Philip Nadeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060025469
    Abstract: Blood cholesterol levels are correlated with production of amyloid ? protein (A?), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A?, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A?.
    Type: Application
    Filed: September 22, 2005
    Publication date: February 2, 2006
    Inventors: Bruce Yankner, Philip Nadeau
  • Publication number: 20020183379
    Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels, Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.
    Type: Application
    Filed: July 14, 2002
    Publication date: December 5, 2002
    Applicant: Children's Medical Center Corporation
    Inventors: Bruce A. Yankner, Philip Nadeau
  • Publication number: 20020120003
    Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.
    Type: Application
    Filed: February 28, 2002
    Publication date: August 29, 2002
    Applicant: Children's Medical Center Corporation
    Inventors: Bruce A. Yankner, Philip Nadeau
  • Patent number: 6440387
    Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: August 27, 2002
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce A. Yankner, Philip Nadeau
  • Publication number: 20020081263
    Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.
    Type: Application
    Filed: January 28, 1999
    Publication date: June 27, 2002
    Inventors: BRUCE A. YANKNER, PHILIP NADEAU
  • Patent number: 6080778
    Abstract: Blood cholesterol levels are correlated with production of amyloid .beta. protein (A.beta.), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A.beta., thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A.beta..
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: June 27, 2000
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce A. Yankner, Philip Nadeau